Application
SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.
Biochem/physiol Actions
Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
5, 25 mg in glass bottle
This product has met the following criteria to qualify for the following awards: